TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15786480

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) combined with photodynamic therapy (PDT) using systemic 5-aminolaevulinic acid (5-ALA) as the photosensitiser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) alone
Number of subjects: 0
Study: 12366728

Group type: COMPARATOR
Intervention: Topiramate 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topiramate 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9396404

Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 489

Group type: COMPARATOR
Intervention: Evaluation committee (EC) review
Number of subjects: 489
Study: 8197239

Group type: EXPERIMENTAL
Intervention: Roland‐Morris (RM) questionnaire
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oswestry (OSW) questionnaire
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Jan van Breemen Institute (JVB) pain questionnaire
Number of subjects: 88

Group type: COMPARATOR
Intervention: Jan van Breemen Institute (JVB) function questionnaire
Number of subjects: 88
Study: 2454362

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 16
Study: 30721231

Group type: EXPERIMENTAL
Intervention: EuroFIT intervention (12-week, group-based programme delivered in 12 weekly 90-minute sessions)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: EuroFIT intervention
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Comparison group (12-month waiting list)
Number of subjects: 1113
Study: 29076760

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23681925

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural guided self-help plus psychopharmacotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Psychopharmacotherapy alone
Number of subjects: 90
Study: 22269589

Group type: EXPERIMENTAL
Intervention: Positive-affect/self-affirmation (PA) intervention group
Number of subjects: 242

Group type: COMPARATOR
Intervention: Patient education (PE) control group
Number of subjects: 242
Study: 19404806

Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine (total volume 106 mL) infiltrated intraoperatively
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine injected intraarticularly via a catheter 21 hours postoperatively
Number of subjects: 40
Study: 17984806

Group type: EXPERIMENTAL
Intervention: 30 mug Vi polysaccharide vaccine (revaccination)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide vaccine (primary vaccination)
Number of subjects: 998
Study: 15522941

Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline levels of CRP
Number of subjects: 40
Study: 11589260

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 9884851

Group type: EXPERIMENTAL
Intervention: Morphine 0.2 mg mL‐1 plus lignocaine 3.2 mg mL‐1 (group ML)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 0.2 mg mL‐1 (group M)
Number of subjects: 50
Study: 8052119

Group type: EXPERIMENTAL
Intervention: Incremental exercise (INC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Constant load exercise (CL)
Number of subjects: 9
Study: 2856056

Group type: EXPERIMENTAL
Intervention: Clonidine + Fenfluramine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fenfluramine alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clonidine alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo Clonidine
Number of subjects: 6
Study: 8157728

Group type: EXPERIMENTAL
Intervention: Phosphate/Etidronate
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Placebo/Etidronate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo/Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Phosphate/Placebo
Number of subjects: 68
Study: 377521

Group type: EXPERIMENTAL
Intervention: Loperamide (Imodium; (Janssen) Ethnor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31813739

Group type: EXPERIMENTAL
Intervention: IC‐ISBT (image-based combined intracavitary-interstitial brachytherapy)
Number of subjects: 94
Study: 30723912

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 198

Group type: COMPARATOR
Intervention: Vaginal dinoprostone insert
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study: 28835029

Group type: EXPERIMENTAL
Intervention: Subgingival glycine air polishing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasonic scaling combined with 0.12% chlorhexidine rinsing
Number of subjects: 22
Study: 25828348

Group type: EXPERIMENTAL
Intervention: 150 mg losartan daily
Number of subjects: 3834

Group type: EXPERIMENTAL
Intervention: 50 mg losartan daily
Number of subjects: 3834

Group type: COMPARATOR
Intervention: High dose losartan
Number of subjects: 3834
Study: 23955995

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Glipizide GITS
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Metformin (lean subgroup, BMI < 25 kg/m(2))
Number of subjects: 160
Study: 21422418

Group type: EXPERIMENTAL
Intervention: Anthracycline (epirubicin) monotherapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: TOP2A amplification
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: A-Score combining TOP2A gene signature and two other signatures
Number of subjects: 149
Study: 19410976

Group type: EXPERIMENTAL
Intervention: (1,3)(1,6)-beta-D-glycan (BDG) 3 x 0.5 g daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (waxy maize starch) 3 x 0.5 g daily for 4 weeks
Number of subjects: 12
Study: 17912137

Group type: EXPERIMENTAL
Intervention: Various stroke rehabilitation interventions (specific interventions not detailed)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Previously published assessment tools
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Study specific assessment tools
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Core of frequently cited tools
Number of subjects: 491
Study: 16043724

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 87
Study: 11527891

Group type: EXPERIMENTAL
Intervention: HMG (150 IU) after day 8 of stimulation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rFSH (375 IU) after day 8 of stimulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (40 BMI and age matched patients with optimal ovarian response)
Number of subjects: 43
Study: 9272895

Group type: EXPERIMENTAL
Intervention: Home visitation by nurses during pregnancy and infancy
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Home visitation by nurses
Number of subjects: 324
Study: 8197931

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy after hormonal treatment (560 mg of estramustine phosphate daily for 6 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 127
Study: 3110382

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 96
Study: 31011944

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - brief (15 min) mindfulness body-scan audio
Number of subjects: 220

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 220
Study: 29093779

Group type: EXPERIMENTAL
Intervention: Autografts
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of HA and DBM
Number of subjects: 35
Study: 26682289

Group type: EXPERIMENTAL
Intervention: Gentle foaming HMP-containing facial cleanser with fragrance
Number of subjects: 161

Group type: COMPARATOR
Intervention: Benchmark gentle, fragrance-free, nonfoaming cleanser
Number of subjects: 161
Study: 23784924

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 16 mg/kg/day (≤1000 mg) for 3 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 20947156

Group type: EXPERIMENTAL
Intervention: 3-step and 2-step etch-and-rinse systems
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2-step/3-step self-etching systems
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prolonged water storage of specimens
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: μTBS values after 8 h and 6 months of storage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: μTBS values
Number of subjects: 36
Study: 19638088

Group type: EXPERIMENTAL
Intervention: EUS plus ERC in a single session
Number of subjects: 80

Group type: COMPARATOR
Intervention: EUS plus ERC in two separate sessions
Number of subjects: 80
Study: 17148536

Group type: EXPERIMENTAL
Intervention: Tailored CD-ROM educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12953307

Group type: EXPERIMENTAL
Intervention: CDDP/epi gel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 87
Study: 10081698

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal treatment (NHT) for three months
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no preoperative therapy)
Number of subjects: 139
Study: 7730488

Group type: EXPERIMENTAL
Intervention: Eradication of H pylori
Number of subjects: 66
Study: 1838772

Group type: EXPERIMENTAL
Intervention: Couple therapy (n = 33), consisting of five monthly sessions attended by two family therapists.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group without couple therapy (n = 30).
Number of subjects: 63
Study: 7275460

Group type: EXPERIMENTAL
Intervention: Low-calorie diet consisting entirely of protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-calorie diet consisting of protein plus carbohydrate
Number of subjects: 0
Study: 31873952

Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks of combined resistance and aerobic exercise)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 30345673

Group type: EXPERIMENTAL
Intervention: Holograms
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 3‐DPDFs
Number of subjects: 179

Group type: COMPARATOR
Intervention: Printed images
Number of subjects: 179
Study: 27618248

Group type: EXPERIMENTAL
Intervention: ApPA-AvSB condition
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ApSB-AvPA condition
Number of subjects: 115

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 115
Study: 24622016

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 0.5 mg/1 ml
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 2 mg/1 ml
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium Chloride (NS) 0.9% solution (1 ml)
Number of subjects: 90
Study: 23278583

Group type: EXPERIMENTAL
Intervention: Extended transsternal thymectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20528293

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure (VRE) therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Present‐centered therapy (PCT)
Number of subjects: 11
Study: 18808630

Group type: EXPERIMENTAL
Intervention: Music group (listened to selected sedative music using headphones)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (worn headphones without music)
Number of subjects: 44
Study: 16104916

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises with biofeedback and lifestyle changes
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lifestyle changes only (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (after crossover from control)
Number of subjects: 55
Study: 11921321

Group type: EXPERIMENTAL
Intervention: Antipsychotic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical methods for cost-effectiveness analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-tailed t test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMCB confidence interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fieller's theorem
Number of subjects: 0
Study: 10037349

Group type: EXPERIMENTAL
Intervention: Cervical fluorescence measurement in women with no history of cervical dysplasia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Previously reported diagnostic algorithms
Number of subjects: 54
Study: 7745513

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 232
Study: 1646182

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT) 60 mg daily (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P) (n = 12)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study: 6941408

Group type: EXPERIMENTAL
Intervention: 8 mg domperidone i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 10
Study: 31085108

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Non-bevacizumab-based regimens
Number of subjects: 139
Study: 28249030

Group type: EXPERIMENTAL
Intervention: Fixed low dose ESA (4000 IU epoetin alfa equivalent weekly)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Fixed high dose ESA (18,000 IU epoetin alfa equivalent weekly)
Number of subjects: 656
Study: 26934484

Group type: EXPERIMENTAL
Intervention: Maternal height <147.5 cm
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Mothers with no education
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Conceived in the pre-monsoon season
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Height-for-age Z-scores (HAZ)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Height-for-age difference in cm (HAD)
Number of subjects: 1054
Study: 25161160

Group type: EXPERIMENTAL
Intervention: Metformin plus voglibose
Number of subjects: 22

Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 22
Study: 22935052

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg orally three times daily for 28 days
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo 10 mg orally three times daily for 14 days followed by Domperidone 10 mg orally three times daily for 14 days
Number of subjects: 560
Study: 19834698

Group type: EXPERIMENTAL
Intervention: Dopaminergic drugs (e.g., levodopa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondopaminergic drugs (e.g., folic acid, methylphenidate, aplindore, levetiracetam, Neu 120)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly developed drugs with known mode of action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large-scale, well-designed, multicenter trials
Number of subjects: 0
Study: 17482465

Group type: EXPERIMENTAL
Intervention: Tamoxifen or Raloxifene
Number of subjects: 33
Study: 15764958

Group type: EXPERIMENTAL
Intervention: 600 mg of Abacavir (ABC) administered once daily
Number of subjects: 770

Group type: COMPARATOR
Intervention: 300 mg of Abacavir (ABC) administered twice daily
Number of subjects: 770
Study: 12169964

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin C (DSMMC group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin C (DS group)
Number of subjects: 90
Study: 10641957

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (INTERCEPT trial)
Number of subjects: 0
Study: 1453405

Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion
Number of subjects: 53
Study: 3902784

Group type: EXPERIMENTAL
Intervention: Multidisciplinary management involving a doctor, physiotherapist, psychologist, and social worker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30389429

Group type: EXPERIMENTAL
Intervention: Toothpaste containing enzymes and proteins
Number of subjects: 0
Study: 29596217

Group type: EXPERIMENTAL
Intervention: $5 financial incentive for HIV testing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: $10 financial incentive for HIV testing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: $15 financial incentive for HIV testing
Number of subjects: 60

Group type: COMPARATOR
Intervention: No financial incentives
Number of subjects: 60
Study: 26932230

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study: 26178160

Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg orally each night for 1 week
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo orally each night for 1 week
Number of subjects: 72
Study: 24093737

Group type: EXPERIMENTAL
Intervention: Systematic relaxation techniques (reading relaxing sentences during recovery)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no relaxation techniques)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Systematic relaxation techniques
Number of subjects: 124
Study: 20679619

Group type: EXPERIMENTAL
Intervention: EOC + P (epirubicin 50 mg/m(2), oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2)/d + P 9 mg/kg every 3 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: EOC + P (DL-1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: EOC + P (DL-2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: EOC (standard dose)
Number of subjects: 29
Study: 18215666

Group type: EXPERIMENTAL
Intervention: Primary intraosseous injection of 1.4 mL of 2% lidocaine with epinephrine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Repeated intraosseous injection given 30 minutes after the primary injection
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mock injection at 30 minutes
Number of subjects: 55
Study: 16618470

Group type: EXPERIMENTAL
Intervention: Active Physical Treatment (APT, n = 52)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT, n = 55)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Combined Treatment (CT, n = 55)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Waiting List (WL, n = 49)
Number of subjects: 211
Study: 14725386

Group type: EXPERIMENTAL
Intervention: New toothbrush plus plaque disclosing tablet (SIGNAL Integral)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste and saliva test strips
Number of subjects: 21

Group type: COMPARATOR
Intervention: Marketed toothbrush (Oral B Cross Action)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no saliva test strips)
Number of subjects: 21
Study: 10758969

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1216
Study: 9227926

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection or ablation of endometriosis
Number of subjects: 341

Group type: COMPARATOR
Intervention: Diagnostic laparoscopy only
Number of subjects: 341
Study: 8219659

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg/day) after placebo treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3305057

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), peroral dose 200 mg three times daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31945066

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Raltegravir (RAL)
Number of subjects: 822
Study: 29249276

Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin (600 mg or 900 mg per day for 2 weeks)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin
Number of subjects: 758
Study: 27350131

Group type: EXPERIMENTAL
Intervention: Step It Up intervention (delivered during NHS Health Check)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: NHS Health Check only (control arm)
Number of subjects: 1140
Study: 24814601

Group type: EXPERIMENTAL
Intervention: Immediate weight-bearing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Affected limb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel ultrasound measurement
Number of subjects: 0
Study: 22820788

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 400 mg once daily for 48 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21105284

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bepotastine (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18275682

Group type: EXPERIMENTAL
Intervention: Supraphysiological doses of PYY3-36
Number of subjects: 6
Study: 15718036

Group type: EXPERIMENTAL
Intervention: Glu/Glu genotype in late onset AD (LOAD) patients
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Patients with AD
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Patients with LOAD
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Glu/Glu homozygous genotype
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: LOAD patients
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Glu/Glu genotype
Number of subjects: 405
Study: 12573274

Group type: EXPERIMENTAL
Intervention: Risk models for death
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Risk models for death or myocardial infarction (MI)
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Risk models for death, MI, or severe recurrent ischaemia (SRI)
Number of subjects: 15904